Our sights are set on creating medicines that will improve patients' ability to manage their disease.
KalVista is building a pipeline of novel oral, small molecule protease inhibitors through preclinical and clinical development as potential best-in-class treatments for a range of diseases, beginning with hereditary angioedema (HAE).
All our drug programs are internally developed by our R&D team, resulting in full rights and long-term patent protection.
YOU ARE NOW LEAVING KALVISTA.COM
You are now being directed to another KalVista website that contains information about specific treatment(s)